An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies With HRAS Mutations

Trial Profile

An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies With HRAS Mutations

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs Tipifarnib (Primary)
  • Indications Head and neck cancer; Solid tumours; Squamous cell cancer; Thyroid cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Kura Oncology
  • Most Recent Events

    • 07 Nov 2017 According to a Kura Oncology media release, updated results from this trial will be presented at the Multidisciplinary Head and Neck Cancers Symposium in February 2018.
    • 27 Oct 2017 Results ( data cutoff date of October 4, 2017) published in a Kura Oncology media release.
    • 27 Oct 2017 According to a Kura Oncology media release, updated preliminary results from the study were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top